Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Babiskin AH"'
Autor:
Walenga RL; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Electronic address: Ross.Walenga@fda.hhs.gov., Babiskin AH; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Boyce HJ; Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Feng X; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Zidan A; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Kamal NS; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Xu X; Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Kim MJ; Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Zhao L; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Dec 23. Date of Electronic Publication: 2024 Dec 23.
Autor:
Walenga RL; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Ross.Walenga@fda.hhs.gov., Babiskin AH; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Bhoopathy S; Pharmaron US Lab Services and CGT, Exton, Pennsylvania, USA., Clarke JF; Simcyp Division, Certara UK, Sheffield, UK., De Backer J; FLUIDDA INC., New York, NY, USA., Ducharme M; Learn and Confirm Inc., St-Laurent, Québec, Canada.; University of Montréal, Montréal, Québec, Canada., Kelly M; Global Inhalation R&D, Teva, London, UK., Le Merdy M; Simulations Plus, Inc., Lancaster, California, USA., Yoon M; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Roy P; Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Publikováno v:
The AAPS journal [AAPS J] 2024 Jan 04; Vol. 26 (1), pp. 12. Date of Electronic Publication: 2024 Jan 04.
Autor:
Walenga RL; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Babiskin AH; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Zhao L; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Jun; Vol. 8 (6), pp. 359-370. Date of Electronic Publication: 2019 May 21.
Autor:
Walenga RL; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993., Babiskin AH; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993. Electronic address: Andrew.Babiskin@fda.hhs.gov., Zhang X; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993., Absar M; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993., Zhao L; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993., Lionberger RA; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, Maryland 20993.
Publikováno v:
Journal of pharmaceutical sciences [J Pharm Sci] 2019 Jan; Vol. 108 (1), pp. 620-629. Date of Electronic Publication: 2018 Oct 29.
Autor:
Babiskin AH; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, 20993., Zhang X; Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, 20993.
Publikováno v:
Journal of pharmaceutical sciences [J Pharm Sci] 2015 Sep; Vol. 104 (9), pp. 3170-82. Date of Electronic Publication: 2015 May 13.
Autor:
Babiskin AH; Division of Chemistry and Chemical Engineering, 1200 E. California Blvd., MC 210-41, California Institute of Technology, Pasadena, CA 91125, USA., Smolke CD
Publikováno v:
Nucleic acids research [Nucleic Acids Res] 2011 Oct; Vol. 39 (19), pp. 8651-64. Date of Electronic Publication: 2011 Jul 06.
Autor:
Babiskin AH; Division of Chemistry and Chemical Engineering, 1200 E. California Blvd., MC 210-41, California Institute of Technology, Pasadena, CA 91125, USA., Smolke CD
Publikováno v:
Nucleic acids research [Nucleic Acids Res] 2011 Jul; Vol. 39 (12), pp. 5299-311. Date of Electronic Publication: 2011 Feb 25.
Autor:
Babiskin AH; Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA., Smolke CD
Publikováno v:
Molecular systems biology [Mol Syst Biol] 2011 Mar 01; Vol. 7, pp. 471.